Fatty Acid Metabolic Reprogramming in Rheumatoid Arthritis: Integrating Inflammation, Resolution Failure, and Joint Destruction Authors: Tingting Li, Guanghuan Li, Yuyao Yang, Liang Han, Pan Shen, Xin Ba, Weiji Lin, Jiahui Yan, Ruiyuan Zhang, Simin Ma, Shenghao Tu, Kai Qin Published: 2026 ABSTRACT AbstractRheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovitis and progressive structural joint damage. Its pathology involves immune-cell infiltration, pannus formation, cartilage degradation, and bone destruction. Although autoantibodies, inflammatory cytokines, and aberrant immune activation are central to RA pathogenesis, they do not fully explain the persistence of synovitis, defective inflammation resolution, or structural joint damage in some patients. Emerging evidence indicates that fatty acid metabolic reprogramming may actively shape RA-related cellular dysfunction by linking lipid substrate availability, membrane remodeling, mitochondrial metabolism, oxidative stress, and lipid mediator generation. This review organizes current evidence within a cell-specific immune–synovial–bone destruction framework. In immune cells, alterations in fatty acid uptake and transport, de novo lipogenesis, fatty acid oxidation, and lipid mediator generation influence monocyte/macrophage-driven inflammatory amplification, T-cell effector responses and regulatory imbalance, and potential B-cell contributions to autoimmunity. In RA fibroblast-like synoviocytes, reprogrammed fatty acid metabolism supports proliferation, migration, invasion, inflammatory mediator production, and matrix degradation, thereby promoting synovial aggression. In osteoclast-lineage cells, fatty acid oxidation and related metabolic adaptations facilitate precursor fusion and bone resorption. In addition, an imbalance between arachidonic acid-derived pro-inflammatory mediators and eicosapentaenoic acid- and docosahexaenoic acid-derived specialized pro-resolving mediators may contribute to persistent inflammation and defective resolution. By integrating inflammatory amplification, defective resolution, synovial aggression, and bone destruction, this review highlights fatty acid metabolism as a context- and cell-dependent regulator of RA progression. Potential therapeutic approaches include limiting excessive fatty acid uptake and de novo lipogenesis, selectively modulating fatty acid oxidation, restoring pro-resolving lipid mediator balance, targeting relevant lipid-sensing receptors, and modulating microbiota-derived fatty acid metabolites. These strategies may complement existing anti-inflammatory and immunomodulatory therapies, although successful translation will require cell-selective targeting, disease-stage stratification, biomarker-guided patient selection, and careful safety evaluation. Introduction Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation, immune cell infiltration, pannus formation, and bone erosion.1 Inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and interleukin-17 (IL-17), together with autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs), are central to inflammatory amplification and disease progression in RA.2–4 However, immune signaling abnormalities alone do not fully explain the persistence of synovitis, the aggressive and apoptosis-resistant phenotype of RA fibroblast-like synoviocytes (RA-FLS), or the progressive structural damage observed in some patients.5–7 Evidence suggests that the RA joint is not merely a passive site of immune activation, but a pathological niche shaped by inflammatory mediators, infiltrating immune cells, synovial stromal cells, pannus formation, osteoclast-lineage cells, and metabolic stress.8–10 Within this niche, immune signaling, cell-cell interactions, and local metabolic pressure converge to sustain chronic synovial inflammation and progressive joint destruction.11,12 The RA synovial microenvironment displays marked features of metabolic remodeling. Persistent inflammation and pannus formation expose local tissues to sustained hypoxia, accompanied by enhanced glycolysis, lactate accumulation, nutrient competition, oxidative stress, lipid accumulation, and altered lipid mediator availability. In this review, metabolic reprogramming refers to inflammation-driven and cell-intrinsic changes in substrate uptake, intracellular metabolic flux, biosynthetic allocation, oxidative metabolism, lipid storage, and metabolite or mediator production that enable RA-related cells to acquire or maintain pathological functional states. This concept differs from transient physiological metabolic variation because it supports disease-related cellular phenotypes. In the context of fatty acid metabolism, such reprogramming includes altered fatty acid uptake and transport, de novo lipogenesis, mitochondrial and peroxisomal fatty acid β-oxidation (FAO), lipid droplet storage, membrane lipid remodeling, and fatty acid-derived mediator generation. These changes may support inflammatory amplification, immune imbalance, RA-FLS aggressiveness, defective resolution, and osteoclast-mediated bone destruction. Under these conditions, RA-FLS, monocytes/macrophages, T cells, osteoclast-lineage cells, and, potentially, B cells may adapt their energy acquisition and biosynthetic programs to support pathological functions, including abnormal proliferation, migration and invasion, inflammatory cytokine secretion, antibody responses, and bone resorption.13–18 Importantly, lipid-related metabolic alterations may emerge before clinically apparent arthritis develops. Studies of presymptomatic individuals and autoantibody-positive individuals at risk of RA indicate that systemic lipid profiles, synovial lipid metabolism-related programs, and fibroblast lipid handling may already be altered before clinical arthritis.19–22 These observations raise the possibility that fatty acid metabolic reprogramming participates in disease development rather than merely reflecting established synovitis; the supporting evidence and its limitations are discussed in Evidence for Fatty Acid Metabolic Remodeling in RA. More broadly, RA pathogenesis involves not only aberrant immune-cell activation, but also metabolic reprogramming across multiple pathogenic cell types.23 Although previous studies on RA immunometabolism have largely focused on enhanced glycolysis and glucose metabolism, fatty acid metabolism has emerged as a regulatory network linking energy supply, membrane lipid remodeling, mitochondrial homeostasis, oxidative stress, and lipid mediator generation. Fatty acids can be oxidized in mitochondria or peroxisomes, incorporated into membrane phospholipids, stored in lipid droplets, or converted into bioactive lipid mediators through cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 pathways.24–26 These metabolic fates have functional consequences beyond energy production. They influence lipid raft signaling, cytoskeletal remodeling, endocytosis, inflammatory transcriptional programs, efferocytosis, and tissue repair.27 Therefore, fatty acid metabolism should be interpreted as a regulatory network that connects cellular metabolic state with inflammatory and tissue-destructive functions.28,29 A central point of this review is that fatty acid metabolism in RA is not uniformly pathogenic or protective. The same metabolic pathway may have divergent effects depending on cell type, substrate source, mitochondrial state, disease stage, and local inflammatory context.30 For example, enhanced FAO may support proinflammatory or aggressive RA-FLS phenotypes and osteoclast precursor fusion, whereas impaired FAO in regulatory T (Treg) cells may weaken immune tolerance.17,31–33 Similarly, arachidonic acid (AA)-derived mediators can amplify synovial inflammation, whereas ω-3 polyunsaturated fatty acid (PUFA)-derived specialized pro-resolving mediators (SPMs) can promote inflammation resolution and tissue repair.34,35 These contrasting effects underscore the need for cell-selective and context-dependent interpretation of fatty acid metabolic changes. Previous reviews have discussed lipid profiles, cardiovascular risk, individual lipid mediators, ferroptosis-related mechanisms, or broad immunometabolic changes in RA.30,36,37 However, relatively few have integrated fatty acid metabolic reprogramming into a cell-specific immune–synovial–bone destruction framework that links lipid substrate handling and lipid mediator imbalance to immune-cell activation, RA-FLS-driven synovial aggression, defective resolution, and osteoclast-mediated bone destruction.6,7,38 Important questions also remain unresolved, including whether specific metabolic alterations represent causal drivers or compensatory responses, how these alterations vary across cell states and disease stages, whether preclinical metabolic changes predict progression to clinical arthritis, and how pathogenic fatty acid pathways can be targeted without disrupting protective metabolic functions. To address these gaps, this review applies an immune–synovial–bone destruction framework to examine how fatty acid uptake and transport, de novo lipogenesis, FAO, lipid storage, and fatty acid-derived mediator generation contribute to inflammatory amplification, persistent synovitis, defective resolution, and structural joint damage in RA. We focus on monocytes/macrophages, T cells, B cells, RA-FLS, osteoclast-lineage cells, and lipid mediator networks because these components represent the major inflammatory, immune-regulatory, stromal, resolution-related, and bone-destructive compartments in RA pathogenesis. Figure 1A summarizes the core fatty acid metabolic routes, including fatty acid uptake and transport, de novo lipogenesis, fatty acid β-oxidation, and lipid mediator generation, whereas Figure 1B maps their cell-specific alterations onto inflammatory amplification, immune dysregulation, defective resolution, synovial aggression, and bone destruction. We summarize evidence from clinical, animal, and cellular studies and evaluate the therapeutic potential of restricting excessive fatty acid uptake and de novo lipogenesis, selectively modulating FAO, restoring lipid mediator balance toward pro-resolving pathways, targeting lipid-sensing receptors, and regulating microbiota-derived fatty acid metabolites. These strategies may offer cell-selective therapeutic opportunities that complement existing anti-inflammatory and immunomodulatory treatments, while the underlying metabolic alterations may also support biomarker development and disease-stage stratification. Their clinical translation will require mechanistic validation, targeted delivery, and careful safety assessment.30,39 Figure 1Fatty acid metabolic reprogramming links inflammatory amplification, defective resolution, synovial aggression, and bone destruction in rheumatoid arthritis. (A) Core fatty acid metabolic routes relevant to rheumatoid arthritis (RA). Fatty acid uptake through CD36, FATPs/SLC27A family members, and FABPs provides free fatty acids for membrane remodeling, energy metabolism, and cellular signaling. De novo lipogenesis converts citrate-derived acetyl-CoA into malonyl-CoA through ACC, followed by FASN-mediated fatty acid synthesis. Mitochondrial fatty acid β-oxidation is supported by CPT1A, whereas ACOX1 participates in peroxisomal β-oxidation. In parallel, AA-derived inflammatory mediators, including PGE2, leukotrienes, and HETEs, and EPA/DHA-derived SPMs contribute to the balance between inflammatory amplification and resolution. (B) Cell-specific metabolic alterations and pathological consequences in RA. In monocytes/macrophages, increased carnitine-related metabolites and potential FAO-related adaptation are associated with enhanced production of TNF-α, IL-1β, IL-6, CCL2, and CCL20, thereby contributing to inflammatory amplification. In T cells, ACC1-dependent fatty acid synthesis promotes Th17 differentiation and IL-17 production, whereas impaired CPT2-related mitochondrial FAO is associated with reduced Treg immunosuppressive function. Potential B-cell involvement may contribute to autoantibody production and immune dysregulation, although direct RA-specific evidence remains limited. In RA-FLS, increased CD36 expression, enhanced FASN-related lipogenesis, and context-dependent FAO support proliferation, migration, invasion, MMP production, inflammatory cytokine release, and RANKL expression, thereby promoting synovial aggression. An imbalance between COX-2/mPGES-1-derived PGE2 and SPM-associated pro-resolving pathways may contribute to defective resolution. In osteoclast-lineage cells, CPT1A-mediated FAO supports osteoclast precursor fusion and bone-resorptive activity, whereas EPA/DHA may inhibit osteoclastogenesis. Together, these cell- and context-dependent alterations connect inflammatory amplification, immune dysregulation, defective resolution, synovial aggression, and bone destruction in RA. The schematic summarizes representative mechanisms rather than an exhaustive list of fatty acid-related pathways. In the schematic, blue arrows indicate metabolic transport or conversion, black pointed arrows indicate promotion or activation, flat-headed arrows indicate inhibition, and ↑ and ↓ indicate increased and decreased activity or expression, respectively. Created with BioRender.com.The two-panel diagram is positioned beside a cross-section of an inflamed rheumatoid joint. Panel A presents four fatty acid metabolic routes: fatty acid uptake and transport through CD36, FATPs/SLC27A, and FABPs; de novo lipogenesis from acetyl-CoA to malonyl-CoA and fatty acids through ACC and FASN; mitochondrial CPT1A-mediated and peroxisomal ACOX1-mediated fatty acid beta-oxidation; and lipid mediator generation, with arachidonic acid-derived PGE2, leukotrienes, and HETEs contrasted with EPA/DHA-derived specialized pro-resolving mediators. Panel B links cell-specific metabolic alterations to rheumatoid arthritis pathology. Increased carnitine-related metabolites and potential FAO-related adaptation in monocytes/macrophages contribute to inflammatory amplification. ACC1-dependent fatty acid synthesis promotes Th17 differentiation, whereas impaired CPT2-related mitochondrial FAO reduces regulatory T-cell immunosuppressive function. Potential B-cell involvement may contribute to autoantibody production and immune dysregulation. Increased CD36, FASN-related lipogenesis, and context-dependent FAO in RA-FLS promote synovial aggression. An imbalance between PGE2 and pro-resolving mediators contributes to defective resolution. CPT1A-mediated FAO supports osteoclast fusion and bone resorption, whereas EPA/DHA may inhibit osteoclastogenesis. Blue arrows indicate metabolic transport or conversion, black arrows indicate promotion or activation, flat-headed lines indicate inhibition, and upward or downward arrows indicate increased or decreased activity or expression.Two-panel schematic of fatty acid metabolic routes and cell-specific pathological consequences in rheumatoid arthritis..Abbreviations: AA, arachidonic acid; ACC, acetyl-CoA carboxylase; ACC1, acetyl-CoA carboxylase 1; ACOX1, acyl-CoA oxidase 1; ACPA, anti-citrullinated protein antibodies; CCL2, C-C motif chemokine ligand 2; CCL20, C-C motif chemokine ligand 20; CD36, cluster of differentiation 36; CoA, coenzyme A; COX, cyclooxygenase; COX-2, cyclooxygenase-2; CPT1A, carnitine palmitoyltransferase 1A; CPT2, carnitine palmitoyltransferase 2; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FABPs, fatty acid-binding proteins; FAO, fatty acid β-oxidation; FASN, fatty acid synthase; FATPs/SLC27A, fatty acid transport proteins/solute carrier family 27A; HETEs, hydroxyeicosatetraenoic acids; IL, interleukin; LOX, lipoxygenase; MMPs, matrix metalloproteinases; mPGES-1, microsomal prostaglandin E synthase-1; P450, cytochrome P450; PGE2, prostaglandin E2; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; RANKL, receptor activator of nuclear factor-κB ligand; RF, rheumatoid factor; SPMs, specialized pro-resolving mediators; Th17, T helper 17; TNF-α, tumor necrosis factor-α; Treg, regulatory T cell. Fatty acid metabolic reprogramming links inflammatory amplification, defective resolution, synovial aggression, and bone destruction in rheumatoid arthritis. (A) Core fatty acid metabolic routes relevant to rheumatoid arthritis (RA). Fatty acid uptake through CD36, FATPs/SLC27A family members, and FABPs provides free fatty acids for membrane remodeling, energy metabolism, and cellular signaling. De novo lipogenesis converts citrate-derived acetyl-CoA into malonyl-CoA through ACC, followed by FASN-mediated fatty acid synthesis. Mitochondrial fatty acid β-oxidation is supported by CPT1A, whereas ACOX1 participates in peroxisomal β-oxidation. In parallel, AA-derived inflammatory mediators, including PGE2, leukotrienes, and HETEs, and EPA/DHA-derived SPMs contribute to the balance between inflammatory amplification and resolution. (B) Cell-specific metabolic alterations and pathological consequences in RA. In monocytes/macrophages, increased carnitine-related metabolites and potential FAO-related adaptation are associated with enhanced production of TNF-α, IL-1β, IL-6, CCL2, and CCL20, thereby contributing to inflammatory amplification. In T cells, ACC1-dependent fatty acid synthesis promotes Th17 differentiation and IL-17 production, whereas impaired CPT2-related mitochondrial FAO is associated with reduced Treg immunosuppressive function. Potential B-cell involvement may contribute to autoantibody production and immune dysregulation, although direct RA-specific evidence remains limited. In RA-FLS, increased CD36 expression, enhanced FASN-related lipogenesis, and context-dependent FAO support proliferation, migration, invasion, MMP production, inflammatory cytokine release, and RANKL expression, thereby promoting synovial aggression. An imbalance between COX-2/mPGES-1-derived PGE2 and SPM-associated pro-resolving pathways may contribute to defective resolution. In osteoclast-lineage cells, CPT1A-mediated FAO supports osteoclast precursor fusion and bone-resorptive activity, whereas EPA/DHA may inhibit osteoclastogenesis. Together, these cell- and context-dependent alterations connect inflammatory amplification, immune dysregulation, defective resolution, synovial aggression, and bone destruction in RA. The schematic summarizes representative mechanisms rather than an exhaustive list of fatty acid-related pathways. In the schematic, blue arrows indicate metabolic transport or conversion, black pointed arrows indicate promotion or activation, flat-headed arrows indicate inhibition, and ↑ and ↓ indicate increased and decreased activity or expression, respectively. Created with BioRender.com. Literature Search Strategy This narrative review was informed by a targeted literature search of PubMed and Web of Science, supplemented by Google Scholar. The databases were searched through June 2026. Search terms combined “rheumatoid arthritis” with terms related to fatty acid metabolism and immunometabolism, including “fatty acid metabolism”, “fatty acid oxidation”, “de novo lipogenesis”, “fatty acid uptake”, “lipid mediators”, “specialized pro-resolving mediators”, “fibroblast-like synoviocytes”, “synovial fibroblasts”, “macrophages”, “T cells”, “B cells”, “osteoclasts”, and “bone erosion”, using Boolean operators as appropriate. Titles and abstracts were screened for relevance, and full texts were reviewed when necessary. Priority was given to original mechanistic studies, lipidomic and metabolomic analyses, animal studies, and human synovial, serum, or clinical studies published in English. Relevant reviews were used to provide background and identify additional primary studies, and the reference lists of selected publications were also screened. Because this was a narrative review rather than a systematic review or meta-analysis, study selection was not conducted according to a formal systematic-review protocol, and no formal risk-of-bias assessment or quantitative synthesis was performed. Fatty Acid Metabolic Reprogramming in RA: Metabolic Routes, Evidence Base, and Conceptual Framework Core Fatty Acid Metabolic Routes Relevant to RA Pathobiology Fatty acid metabolism represents a major component of lipid metabolic remodeling in inflammatory diseases. It includes fatty acid uptake, intracellular transport, activation, de novo synthesis, lipid droplet storage, β-oxidation, and the production of fatty acid-derived lipid mediators. These routes determine how lipid substrates are allocated among membrane remodeling, energy production, lipid storage, redox regulation, inflammatory signaling, and mediator biosynthesis. In inflammatory and proliferative cells, such lipid redistribution can influence cell activation, survival, migration, inflammatory signaling, and tissue-destructive effector functions.25,40 Free fatty acids enter cells through transporters or binding proteins such as cluster of differentiation 36 (CD36), fatty acid transport proteins/solute carrier family 27A members (FATPs/SLC27A), and fatty acid-binding proteins (FABPs). After entering cells, fatty acids are activated to fatty acyl-CoA by long-chain acyl-CoA synthetases (ACSLs), which channel them toward membrane phospholipid synthesis, triglyceride storage, mitochondrial or peroxisomal oxidation, or lipid mediator biosynthesis.41 Thus, fatty acid uptake and activation are not merely substrate-supply steps, but may influence the balance between lipid storage, membrane remodeling, oxidative metabolism, and inflammatory mediator production.25,42 De novo lipogenesis provides another source of fatty acids, particularly in proliferating or persistently activated cells. Citrate-derived acetyl-CoA is converted to malonyl-CoA by acetyl-CoA carboxylase (ACC), followed by fatty acid chain synthesis through fatty acid synthase (FASN).43,44 Stearoyl-CoA desaturase 1 (SCD1) introduces double bonds into saturated fatty acids, whereas sterol regulatory element-binding protein 1 (SREBP1) and related regulatory pathways coordinate lipogenic gene expression.45 These processes support membrane expansion, lipid raft formation, organelle remodeling, and inflammatory signaling, all of which are relevant to immune-cell activation and the aggressive behavior of synovial stromal cells in RA.21 FAO occurs mainly in mitochondria and peroxisomes. Long-chain fatty acyl-CoA requires the carnitine shuttle, including carnitine palmitoyltransferase 1 (CPT1), carnitine-acylcarnitine translocase, and carnitine palmitoyltransferase 2 (CPT2), to enter mitochondria for β-oxidation. Peroxisomal FAO is particularly important for very-long-chain fatty acids and involves enzymes such as acyl-CoA oxidase 1 (ACOX1). By generating acetyl-CoA and reducing equivalents, FAO links lipid catabolism to the tricarboxylic acid cycle, oxidative phosphorylation, redox balance, and mitochondrial signaling.46 Depending on the cell type and inflammatory context, FAO may support either pathogenic functions, such as synovial aggression and osteoclast activity, or protective functions, such as Treg-cell fitness and immune tolerance.17,47,48 Fatty acids also serve as precursors for lipid mediators. AA-derived prostaglandins, leukotrienes, and hydroxyeicosatetraenoic acids (HETEs) can promote leukocyte recruitment, pain sensitization, cytokine production, and bone remodeling.25 By contrast, eicosapentaenoic acid (EPA)- and docosahexaenoic acid (DHA)-derived SPMs, including resolvins, protectins, and maresins, actively promote inflammation resolution, efferocytosis, and tissue repair. Thus, fatty acid metabolic reprogramming in RA includes not only altered energy metabolism, but also redistribution of lipid substrates among membrane remodeling, lipid storage, oxidative metabolism, and inflammatory or pro-resolving mediator generation.49 Evidence for Fatty Acid Metabolic Remodeling in RA Lipidomic and metabolomic studies provide the most direct evidence that RA is associated with both systemic and local joint lipid metabolic remodeling. Abnormal levels of free fatty acids, phospholipids, sphingolipids, glycerolipids, oxidized lipids, and fatty acid-derived mediators have been reported in serum, synovial fluid, and synovial tissues from patients with RA.50–52 These changes suggest that lipid dysregulation in RA is not limited to conventional blood lipid abnormalities, but may also reflect local inflammatory activity, cellular metabolic adaptation within the synovium, and tissue damage within the joint.53 Synovial fluid studies provide more direct evidence for local fatty acid abnormalities. Fatty acid-related metabolites, including isopalmitic acid, myristic acid, and palmitoleic acid, have been identified as candidate molecules distinguishing RA from other inflammatory arthritides.54 Dysregulated fatty acid biosynthesis and unsaturated fatty acid biosynthesis pathways have also been reported in RA synovial fluid, suggesting altered fatty acid synthesis, desaturation, and metabolic fate within the inflamed joint microenvironment.55 Evidence from at-risk cohorts provides temporal support for the involvement of lipid metabolic remodeling in RA development. Plasma metabolomic and lipidomic profiling of presymptomatic individuals who subsequently developed RA identified perturbations in fatty acid β-oxidation and changes in fatty acids, acylcarnitines, lysophosphatidylcholines, phospholipids, and sphingomyelins before symptom onset.19 In autoantibody-positive individuals at risk of RA, synovial tissue showed downregulation of lipid metabolism-related genes and reduced lipid-droplet content, with some alterations associated with subsequent arthritis development.20 Synovial fibroblasts derived from at-risk individuals also exhibited impaired mitochondrial FAO and reduced metabolic flexibility, while more recent work identified enhanced lipolysis and reduced lipid-droplet content in this preclinical setting.21,22 Collectively, these findings suggest that lipid metabolic remodeling may precede clinically apparent arthritis. However, the available studies involved relatively small cohorts and were predominantly observational; therefore, temporal association does not establish that these metabolic alterations causally drive RA development. Some changes may instead reflect systemic preclinical immune activation or emerging subclinical synovial pathology. Longitudinal studies incorporating serial sampling, direct measurements of metabolic flux, and functional validation are needed to clarify causality. In established RA, RA-FLS can also exhibit reduced mitochondrial respiration, impaired fatty acid utilization, decreased metabolic flexibility, and compensatory increases in glucose utilization.21 Experimental models further support the functional relevance of fatty acid metabolic remodeling in RA. In collagen-induced arthritis (CIA), plasma oxylipin profiles are altered, indicating changes in PUFA oxidation products and lipid mediator networks.56 High-fat diet models show that systemic lipid overload can aggravate arthritis and reshape gut microbiota and metabolic pathways.57 Although these models do not directly reflect cell-intrinsic fatty acid metabolism within the RA joint, they suggest that systemic lipid availability can influence arthritis severity and inflammatory metabolism. More direct mechanistic studies indicate that CD36-mediated fatty acid metabolic reprogramming activates RA-FLS, carnitine palmitoyltransferase 1A (CPT1A)-mediated FAO promotes osteoclast precursor fusion and bone resorption, and free fatty acid receptor 4/G protein-coupled receptor 120 (FFAR4/GPR120) activation can alleviate arthritis while improving the T helper 1 (Th1)/T helper 17 (Th17)/regulatory T cell (Treg) balance.17,58 Taken together, these findings support the functional relevance of fatty acid metabolic reprogramming in RA, while emphasizing that its biological consequences depend on cell type, lipid substrate, metabolic fate, and disease context. The translational interpretation of these experimental findings requires caution. CIA reproduces several features of human RA, including autoantibody generation, synovial inflammation, cartilage damage, and bone erosion, but it is induced by collagen/adjuvant immunization in genetically susceptible animals.59 Disease severity can be variable, and no single murine model reproduces the prolonged preclinical phase, cellular heterogeneity, chronic relapsing course, or variable treatment responses of human RA.60 Mechanistic findings from CIA and other arthritis models should therefore be validated across complementary models and, where possible, in primary human cells, synovial tissues, and longitudinal clinical cohorts. An Immune–Synovial–Bone Destruction Framework In this review, we use an immune–synovial–bone destruction framework to organize current evidence on fatty acid metabolic reprogramming in RA. This framework reflects the mutually reinforcing interactions among immune-cell-mediated inflammation, FLS-driven synovial aggression, lipid mediator imbalance, and osteoclast-mediated bone erosion within the metabolically remodeled RA joint microenvironment. Monocytes/macrophages and T cells contribute to inflammatory amplification through cytokine production, chemokine release, and immune-cell recruitment, whereas B cells may participate through autoantibody-related responses and antigen presentation.61,62 RA-FLS promote pannus formation, migration, invasion, cartilage degradation, and pro-osteoclastogenic signaling through mediators such as IL-6, IL-8, matrix metalloproteinases (MMPs), and receptor activator of nuclear factor-κB ligand (RANKL). Osteoclast-lineage cells mediate bone resorption under the influence of RANKL, TNF-α, IL-1β, IL-17, and other inflammatory signals.38,63,64 Fatty acid metabolic reprogramming may influence each component of this framework. In RA-FLS, altered fatty acid uptake, de novo lipogenesis, FAO, lipid handling, and lipid mediator biosynthesis may support invasive and pro-inflammatory phenotypes.31,48 In monocytes/macrophages, changes in lipid availability, fatty acid transport, and mitochondrial substrate use may contribute to chemokine release and inflammatory amplification.16 In T cells, fatty acid synthesis, uptake, and oxidation may shape effector T-cell differentiation, Treg stability, and inflammatory cell death, whereas the role of B-cell fatty acid metabolism in RA remains less well defined.65–67 In osteoclast-lineage cells, CPT1A-mediated FAO may support precursor fusion, membrane trafficking, and bone-resorptive activity.17 Thus, fatty acid metabolic reprogramming provides a metabolic-inflammatory basis for linking inflammatory amplification, synovial aggression, defective resolution, and bone destruction in RA. The major changes, pathological consequences, and evidence across immune cells are summarized in Table 1, whereas RA-FLS, osteoclast-lineage cells, and lipid mediator networks are summarized in Table 2. Table 1Fatty Acid Metabolic Reprogramming in Immune Cells in Rheumatoid ArthritisCell Type/CompartmentFatty Acid-Related ChangesPathological ConsequencesRepresentative Evidence and InterpretationMonocytes/macrophagesAltered lipid availability, carnitine-related metabolites, fatty acid transport, and mitochondrial substrate use.Chemokine production, inflammatory amplification, immune-cell recruitment, and potential osteoclastogenic signaling.RA synovial fluid increases carnitine-related metabolites in hypoxic monocytes and promotes CCL20 secretion; CCL20 may recruit CCR6+ Th17 cells.16,68 Direct evidence for macrophage-intrinsic fatty acid reprogramming in RA synovium remains limited.Th17 cellsEnhanced lactate-driven fatty acid synthesis and ACC1-dependent de novo lipogenesis.Promotion of Th17 differentiation, IL-17 production, and autoimmune inflammation.SLC5A12-mediated lactate uptake promotes fatty acid synthesis and PKM2/STAT3 activation; ACC1 regulates the Th17/Treg fate decision.69–71 Effects may vary by subset, stimulus, and disease stage.CD8+ T cellsIncreased fatty acid uptake and expression of lipid transport or sensing molecules, including FABP4 and GPR84.Enhanced activation, proliferation, cytotoxicity, and inflammatory cytokine production.Blocking fatty acid metabolism, FABP4, or GPR84 reduces pro-inflammatory effector functions in CD8+ T cells from patients with RA.72 Synovial CD8+ T-cell subsets require further validation.Treg cellsImpaired mitochondrial FAO, altered UCP2/CPT2-related metabolism, and reduced CTLA4 surface stability.Reduced immunosuppressive function and impaired immune tolerance.RA Treg dysfunction has been linked to increased UCP2, reduced CPT2 expression or acetylation, impaired FAO, and reduced CTLA4 stability.33 FAO is not uniformly pathogenic; preservation or restoration of FAO may be beneficial in Treg cells.B cellsPotential changes in fatty acid uptake, synthesis, oxidation, and lipid-related nuclear receptor signaling, and microbiota-derived metabolite responses.Possible effects on B-cell activation, antibody responses, regulatory B-cell function, and autoimmune amplification.PPARγ restrains excessive B-cell proliferation and NF-κB signaling; conversely, PPARγ haploinsufficiency enhances B-cell proliferation and aggravates antigen-induced arthritis. Butyrate may suppress arthritis by enhancing AhR-dependent Breg function.73,74 RA-specific evidence remains preliminary; B-cell fatty acid metabolism should therefore be regarded as an emerging area.Abbreviations: ACC1, acetyl-CoA carboxylase 1; AhR, aryl hydrocarbon receptor; Breg, regulatory B cell; CCL20, C-C motif chemokine ligand 20; CCR6, C-C motif chemokine receptor 6; CD8, cluster of differentiation 8; CPT2, carnitine palmitoyltransferase 2; CTLA4, cytotoxic T-lymphocyte-associated protein 4; FABP4, fatty acid-binding protein 4; FAO, fatty acid β-oxidation; GPR84, G protein-coupled receptor 84; IL-17, interleukin-17; NF-κB, nuclear factor-κB; PKM2, pyruvate kinase M2; PPARγ, peroxisome proliferator-activated receptor γ; RA, rheumatoid arthritis; SLC5A12, solute carrier family 5 member 12; STAT3, signal transducer and activator of transcription 3; Th17, T helper 17; Treg, regulatory T cell; UCP2, uncoupling protein 2. Table 2Fatty Acid Metabolic Reprogramming in RA-FLS, Osteoclast-Lineage Cells, and the Lipid Mediator NetworkCell Type/CompartmentFatty Acid-Related ChangesPathological ConsequencesRepresentative Evidence and InterpretationRA-FLSIncreased CD36-related fatty acid influx, enhanced FASN/SREBP1-related lipogenesis, context-dependent FAO changes, and lipid mediator production.Proliferation, migration, invasion, matrix degradation, cytokine release, and pro-osteoclastogenic signaling.CD36-mediated fatty acid influx supports RA-FLS activation; FASN promotes lipid accumulation, mitochondrial fragmentation, ROS, and PI3K/mTOR/NF-κB activation; MiD49/51–CPT1A-related FAO may support invasiveness.31,44,48,75 RA-FLS are a central metabolic node linking synovial aggression, immune amplification, and bone destruction. Most mechanistic evidence remains cell-based or preclinical, and the direction of FAO changes may vary by disease stage and RA-FLS subset.Osteoclast-lineage cellsIncreased CPT1A-mediated mitochondrial FAO, altered lipid droplet storage, and fatty acid species-dependent receptor signaling.Osteoclast precursor fusion, podosome formation, bone resorption, and structural joint damage.CPT1A-mediated FAO promotes precursor fusion through C/EBPβ-dependent clathrin-related membrane trafficking; DHA and FFAR4/GPR120 signaling may suppress osteoclastogenesis.17,76–78 CPT1A represents a promising candidate target, although fatty acid species, receptor signaling, and validation in human RA must be considered.Lipid mediator networkImbalance between AA-derived pro-inflammatory mediators and EPA/DHA-derived SPMs.Inflammatory amplification, pain sensitization, leukocyte recruitment, defective resolution, cartilage injury, and bone remodeling.AA-derived PGE2, leukotrienes, and HETEs may amplify inflammation, whereas resolvins, protectins, and maresins promote resolution and tissue repair.34,35,49,79 Lipid mediator dysregulation should be interpreted as an inflammatory-resolution imbalance rather than a simple change in single metabolites. Causal and clinical evidence linking specific mediator profiles to RA progression remains limited.Abbreviations: AA, arachidonic acid; C/EBPβ, CCAAT/enhancer-binding protein β; CD36, cluster of differentiation 36; CPT1A, carnitine palmitoyltransferase 1A; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FAO, fatty acid β-oxidation; FASN, fatty acid synthase; FFAR4/GPR120, free fatty acid receptor 4/G protein-coupled receptor 120; HETEs, hydroxyeicosatetraenoic acids; MiD49/51, mitochondrial dynamics proteins of 49 and 51 kDa; mTOR, mechanistic target of rapamycin; NF-κB, nuclear factor-κB; PGE2, prostaglandin E2; PI3K, phosphoinositide 3-kinase; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; ROS, reactive oxygen species; SPMs, specialized pro-resolving mediators; SREBP1, sterol regulatory element-binding protein 1. Table 1Fatty Acid Metabolic Reprogramming in Immune Cells in Rheumatoid ArthritisCell Type/CompartmentFatty Acid-Related ChangesPathological ConsequencesRepresentative Evidence and InterpretationMonocytes/macrophagesAltered lipid availability, carnitine-related metabolites, fatty acid transport, and mitochondrial substrate use.Chemokine production, inflammatory amplification, immune-cell recruitment, and potential osteoclastogenic signaling.RA synovial fluid increases carnitine-related metabolites in hypoxic monocytes and promotes CCL20 secretion; CCL20 may recruit CCR6+ Th17 cells.16,68 Direct evidence for macrophage-intrinsic fatty acid reprogramming in RA synovium remains limited.Th17 cellsEnhanced lactate-driven fatty acid synthesis and ACC1-dependent de novo lipogenesis.Promotion of Th17 differentiation, IL-17 production, and autoimmune inflammation.SLC5A12-mediated lactate uptake promotes fatty acid synthesis and PKM2/STAT3 activation; ACC1 regulates the Th17/Treg fate decision.69–71 Effects may vary by subset, stimulus, and disease stage.CD8+ T cellsIncreased fatty acid uptake and expression of lipid transport or sensing molecules, including FABP4 and GPR84.Enhanced activation, proliferation, cytotoxicity, and inflammatory cytokine production.Blocking fatty acid metabolism, FABP4, or GPR84 reduces pro-inflammatory effector functions in CD8+ T cells from patients with RA.72 Synovial CD8+ T-cell subsets require further validation.Treg cellsImpaired mitochondrial FAO, altered UCP2/CPT2-related metabolism, and reduced CTLA4 surface stability.Reduced immunosuppressive function and impaired immune tolerance.RA Treg dysfunction has been linked to increased UCP2, reduced CPT2 expression or acetylation, impaired FAO, and reduced CTLA4 stability.33 FAO is not uniformly pathogenic; preservation or restoration of FAO may be beneficial in Treg cells.B cellsPotential changes in fatty acid uptake, synthesis, oxidation, and lipid-related nuclear receptor signaling, and microbiota-derived metabolite responses.Possible effects on B-cell activation, antibody responses, regulatory B-cell function, and autoimmune amplification.PPARγ restrains excessive B-cell proliferation and NF-κB signaling; conversely, PPARγ haploinsufficiency enhances B-cell proliferation and aggravates antigen-induced arthritis. Butyrate may suppress arthritis by enhancing AhR-dependent Breg function.73,74 RA-specific evidence remains preliminary; B-cell fatty acid metabolism should therefore be regarded as an emerging area.Abbreviations: ACC1, acetyl-CoA carboxylase 1; AhR, aryl hydrocarbon receptor; Breg, regulatory B cell; CCL20, C-C motif chemokine ligand 20; CCR6, C-C motif chemokine receptor 6; CD8, cluster of differentiation 8; CPT2, carnitine palmitoyltransferase 2; CTLA4, cytotoxic T-lymphocyte-associated protein 4; FABP4, fatty acid-binding protein 4; FAO, fatty acid β-oxidation; GPR84, G protein-coupled receptor 84; IL-17, interleukin-17; NF-κB, nuclear factor-κB; PKM2, pyruvate kinase M2; PPARγ, peroxisome proliferator-activated receptor γ; RA, rheumatoid arthritis; SLC5A12, solute carrier family 5 member 12; STAT3, signal transducer and activator of transcription 3; Th17, T helper 17; Treg, regulatory T cell; UCP2, uncoupling protein 2. Fatty Acid Metabolic Reprogramming in Immune Cells in Rheumatoid Arthritis Abbreviations: ACC1, acetyl-CoA carboxylase 1; AhR, aryl hydrocarbon receptor; Breg, regulatory B cell; CCL20, C-C motif chemokine ligand 20; CCR6, C-C motif chemokine receptor 6; CD8, cluster of differentiation 8; CPT2, carnitine palmitoyltransferase 2; CTLA4, cytotoxic T-lymphocyte-associated protein 4; FABP4, fatty acid-binding protein 4; FAO, fatty acid β-oxidation; GPR84, G protein-coupled receptor 84; IL-17, interleukin-17; NF-κB, nuclear factor-κB; PKM2, pyruvate kinase M2; PPARγ, peroxisome proliferator-activated receptor γ; RA, rheumatoid arthritis; SLC5A12, solute carrier family 5 member 12; STAT3, signal transducer and activator of transcription 3; Th17, T helper 17; Treg, regulatory T cell; UCP2, uncoupling protein 2. Table 2Fatty Acid Metabolic Reprogramming in RA-FLS, Osteoclast-Lineage Cells, and the Lipid Mediator NetworkCell Type/CompartmentFatty Acid-Related ChangesPathological ConsequencesRepresentative Evidence and InterpretationRA-FLSIncreased CD36-related fatty acid influx, enhanced FASN/SREBP1-related lipogenesis, context-dependent FAO changes, and lipid mediator production.Proliferation, migration, invasion, matrix degradation, cytokine release, and pro-osteoclastogenic signaling.CD36-mediated fatty acid influx supports RA-FLS activation; FASN promotes lipid accumulation, mitochondrial fragmentation, ROS, and PI3K/mTOR/NF-κB activation; MiD49/51–CPT1A-related FAO may support invasiveness.31,44,48,75 RA-FLS are a central metabolic node linking synovial aggression, immune amplification, and bone destruction. Most mechanistic evidence remains cell-based or preclinical, and the direction of FAO changes may vary by disease stage and RA-FLS subset.Osteoclast-lineage cellsIncreased CPT1A-mediated mitochondrial FAO, altered lipid droplet storage, and fatty acid species-dependent receptor signaling.Osteoclast precursor fusion, podosome formation, bone resorption, and structural joint damage.CPT1A-mediated FAO promotes precursor fusion through C/EBPβ-dependent clathrin-related membrane trafficking; DHA and FFAR4/GPR120 signaling may suppress osteoclastogenesis.17,76–78 CPT1A represents a promising candidate target, although fatty acid species, receptor signaling, and validation in human RA must be considered.Lipid mediator networkImbalance between AA-derived pro-inflammatory mediators and EPA/DHA-derived SPMs.Inflammatory amplification, pain sensitization, leukocyte recruitment, defective resolution, cartilage injury, and bone remodeling.AA-derived PGE2, leukotrienes, and HETEs may amplify inflammation, whereas resolvins, protectins, and maresins promote resolution and tissue repair.34,35,49,79 Lipid mediator dysregulation should be interpreted as an inflammatory-resolution imbalance rather than a simple change in single metabolites. Causal and clinical evidence linking specific mediator profiles to RA progression remains limited.Abbreviations: AA, arachidonic acid; C/EBPβ, CCAAT/enhancer-binding protein β; CD36, cluster of differentiation 36; CPT1A, carnitine palmitoyltransferase 1A; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FAO, fatty acid β-oxidation; FASN, fatty acid synthase; FFAR4/GPR120, free fatty acid receptor 4/G protein-coupled receptor 120; HETEs, hydroxyeicosatetraenoic acids; MiD49/51, mitochondrial dynamics proteins of 49 and 51 kDa; mTOR, mechanistic target of rapamycin; NF-κB, nuclear factor-κB; PGE2, prostaglandin E2; PI3K, phosphoinositide 3-kinase; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; ROS, reactive oxygen species; SPMs, specialized pro-resolving mediators; SREBP1, sterol regulatory element-binding protein 1. Fatty Acid Metabolic Reprogramming in RA-FLS, Osteoclast-Lineage Cells, and the Lipid Mediator Network Abbreviations: AA, arachidonic acid; C/EBPβ, CCAAT/enhancer-binding protein β; CD36, cluster of differentiation 36; CPT1A, carnitine palmitoyltransferase 1A; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FAO, fatty acid β-oxidation; FASN, fatty acid synthase; FFAR4/GPR120, free fatty acid receptor 4/G protein-coupled receptor 120; HETEs, hydroxyeicosatetraenoic acids; MiD49/51, mitochondrial dynamics proteins of 49 and 51 kDa; mTOR, mechanistic target of rapamycin; NF-κB, nuclear factor-κB; PGE2, prostaglandin E2; PI3K, phosphoinositide 3-kinase; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; ROS, reactive oxygen species; SPMs, specialized pro-resolving mediators; SREBP1, sterol regulatory element-binding protein 1. Cell-Specific Fatty Acid Metabolic Reprogramming Within the Immune–Synovial–Bone Destruction Framework Fatty acid metabolic reprogramming affects multiple pathological cell populations in RA by altering lipid substrate uptake, intracellular lipid handling, oxidative metabolism, and lipid mediator production. Within the immune–synovial–bone destruction framework, immune cells contribute to inflammatory amplification and autoimmune imbalance, RA-FLS drive synovial aggression and pannus formation, and osteoclast-lineage cells mediate structural bone damage.63 These processes are connected by cytokines, chemokines, lipid mediators, metabolic substrates, and cell–cell interactions within the inflamed synovial microenvironment. Monocytes/Macrophages: Metabolic Amplifiers of Synovial Inflammation Monocytes and macrophages are major immune populations within the RA synovial inflammatory network. After peripheral monocytes enter the inflamed synovium, they are exposed to hypoxia, lactate accumulation, inflammatory cytokines, immune complexes, and altered lipid substrates. These local cues reshape their metabolic and functional states, promoting inflammatory macrophage phenotypes or mixed pathological states. Activated monocytes/macrophages release TNF-α, IL-1β, IL-6, C-C motif chemokine ligand 2 (CCL2), and C-C motif chemokine ligand 20 (CCL20), thereby contributing to RA-FLS activation, immune-cell recruitment, and osteoclastogenesis.16,80,81 From the perspective of fatty acid metabolism, monocytes/macrophages can be viewed as metabolically responsive inflammatory amplifiers that convert altered lipid availability and fatty acid-related metabolic adaptation into inflammatory and chemotactic outputs.9,10 At the local joint level, RA synovial fluid can directly alter fatty acid-related metabolism in monocytes. Under hypoxic conditions, RA synovial fluid increases carnitine-related metabolites in human monocytes and promotes CCL20 secretion. Because carnitine is required for mitochondrial transport of long-chain fatty acids, these findings link the hypoxic synovial milieu to fatty acid mitochondrial transport, oxidative metabolism, and chemokine production.82 Exogenous carnitine further enhances lipopolysaccharide-induced CCL20 release, supporting the possibility that fatty acid mitochondrial transport and FAO-related adaptation contribute to inflammatory chemokine output. Since CCL20 recruits C-C motif chemokine receptor 6-positive (CCR6⁺) Th17 cells, this pathway may convert synovial metabolic stress into immune-cell recruitment signals, thereby amplifying IL-17-related inflammation and osteoclastogenic responses.16,68 Beyond the joint, macrophage–adipose tissue crosstalk may contribute to systemic immunometabolic abnormalities in RA. Increased macrophage infiltration and crown-like structures have been observed in subcutaneous adipose tissue from patients with RA and are associated with systemic inflammation, autoantibody status, and insulin resistance.83 In arthritis models, elevated circulating free fatty acids, accumulation of CD86⁺CD11b⁺ inflammatory macrophages in white adipose tissue, and impaired adipocyte metabolic function related to peroxisome proliferator-activated receptor γ (PPARγ) and SCD1 suggest that adipose tissue can become an active site of immune–metabolic interaction.84 Impaired adipocyte lipid storage may increase free fatty acid exposure and promote macrophage inflammatory activation, whereas activated macrophages may further disrupt adipocyte differentiation and lipid homeostasis. These systemic alterations do not directly prove macrophage-intrinsic fatty acid metabolic reprogramming within the RA joint, but they suggest that peripheral lipid disturbances may reinforce inflammatory burden in RA.85 Overall, monocyte/macrophage fatty acid-related metabolic adaptation may contribute to synovial inflammation by promoting chemokine production, immune-cell recruitment, and osteoclastogenic signaling. However, direct evidence for macrophage-intrinsic fatty acid metabolic reprogramming in RA remains relatively limited compared with the evidence available for glycolytic remodeling, RA-FLS activation, and osteoclast FAO. Future studies using cell-specific metabolic tracing, single-cell multi-omics, and spatial lipidomics are needed to define how fatty acid uptake, storage, oxidation, and mediator generation regulate macrophage phenotypes in RA synovium. T Cells and Potential B-Cell Involvement: Fatty Acid Metabolism in Autoimmune Imbalance T-cell activation, effector T-cell expansion, and impaired immune tolerance are central to persistent autoimmune responses in RA. In the RA synovial microenvironment, T cells are shaped not only by antigen stimulation and cytokines, but also by hypoxia, lactate accumulation, altered lipid substrates, and nutrient competition. Different T-cell subsets depend on fatty acid metabolism in distinct ways. Th17 cells and CD8⁺ effector or memory T cells may use fatty acid synthesis, uptake, or oxidation to sustain inflammatory function, whereas Treg cells rely more on mitochondrial oxidative metabolism and FAO to maintain immunosuppressive activity.66,86 Th17 differentiation is closely linked to lipid biosynthesis. Lactate accumulating in the RA synovium can enter CD4⁺ T cells through solute carrier family 5 member 12 (SLC5A12), thereby inducing metabolic remodeling characterized by enhanced fatty acid synthesis, nuclear pyruvate kinase M2 (PKM2)/signal transducer and activator of transcription 3 (STAT3) activation, and increased IL-17 production. Blockade of SLC5A12 attenuates experimental arthritis, suggesting that lactate-driven lipid synthesis converts synovial metabolic stress into pathogenic T-cell responses.69,70 Intrinsically, acetyl-CoA carboxylase 1 (ACC1)-mediated fatty acid synthesis regulates the Th17/Treg fate decision; ACC1 inhibition or T-cell-specific ACC1 deletion reduces Th17 generation and favors Treg differentiation.71 Fatty acid and cholesterol biosynthesis may also support Th17 programs by generating lipid ligands required for retinoic acid receptor-related orphan receptor γt (RORγt) activity. Thus, fatty acid synthesis contributes not only to membrane biogenesis, but also to T-cell lineage determination and IL-17-driven inflammation.87 CD8⁺ T cells provide another example of subset-specific fatty acid dependence. Effector and memory CD8⁺ T cells from patients with RA show increased expression of fatty acid transport or sensing molecules such as fatty acid-binding protein 4 (FABP4) and G protein-coupled receptor 84 (GPR84), together with enhanced fatty acid uptake. Blocking fatty acid metabolism, FABP4, or GPR84 reduces CD8⁺ T-cell activation, proliferation, granzyme B expression, and inflammatory cytokine production. These findings extend fatty acid metabolic reprogramming beyond the Th17 axis and suggest that lipid uptake and oxidative utilization can support pro-inflammatory and cytotoxic T-cell functions in RA.72 In contrast, Treg cells require mitochondrial oxidative metabolism and FAO for immune suppression. In RA, Treg dysfunction has been linked to increased uncoupling protein 2 (UCP2) expression, reduced CPT2 expression and acetylation, impaired FAO, and decreased surface stability of cytotoxic T-lymphocyte-associated protein 4 (CTLA4). This metabolic defect weakens Treg suppressive function and may allow effector T-cell responses to persist. Therefore, FAO should not be categorized as uniformly pro-inflammatory or anti-inflammatory; its impact depends on the cell type and functional context.33 Fatty acid overload may also alter T-cell death patterns. In lipid-rich RA synovium, infiltrating CD4⁺ T cells can accumulate fatty acids and form lipid droplets enriched in gasdermin D (GSDMD) and zinc finger DHHC-type palmitoyltransferase 5 (ZDHHC5). These lipid droplets can translocate to the plasma membrane, promote pore formation, and induce lytic cell death, releasing intracellular contents that further stimulate tissue inflammation. This mechanism links fatty acid overload to persistent synovitis through a pathway distinct from the conventional Th17/Treg imbalance.65 Compared with T cells, direct RA-specific evidence for fatty acid metabolic reprogramming in B cells remains limited. Broader immunometabolic studies indicate that fatty acid uptake, synthesis, and oxidation can influence B-cell development, activation, antibody responses, and autoimmune pathology.88 PPARγ, a lipid metabolism-related nuclear receptor involved in lipid metabolism and immune regulation, may restrain excessive B-cell activation and inflammatory signaling. PPARγ haploinsufficiency has been reported to enhance B-cell proliferation and nuclear factor-κB (NF-κB) signaling and to aggravate disease severity in an antigen-induced arthritis model.73 In addition, gut microbiota-derived butyrate may suppress arthritis by enhancing aryl hydrocarbon receptor (AhR)-dependent regulatory B-cell (Breg) function.74 These findings suggest possible B-cell involvement in lipid-related immune regulation, but they do not yet establish direct fatty acid metabolic reprogramming of B cells within RA joints. This remains an important area for future investigation. RA-FLS: Metabolic Drivers of Synovial Aggression FLS are central effector cells in persistent synovial inflammation, pannus formation, cartilage degradation, and structural joint damage in RA.63 Compared with normal synovial fibroblasts, RA-FLS exhibit abnormal proliferation, apoptosis resistance, enhanced migration and invasion, and sustained production of inflammatory and tissue-destructive mediators, including IL-6, IL-8, MMPs, and RANKL.7 Although inflammatory cytokines and immune cell-derived signals are important drivers of RA-FLS activation, metabolic reprogramming helps explain how RA-FLS maintain a stable aggressive phenotype in the inflamed synovial microenvironment.89,90 Enhanced fatty acid uptake is one of the upstream metabolic events supporting RA-FLS activation. CD36, which functions as both a fatty acid transporter and a signaling receptor, is upregulated in RA synovial tissues and RA-FLS. CD36-mediated fatty acid influx can provide substrates for membrane phospholipid synthesis, lipid raft signaling, cytoskeletal remodeling, mitochondrial oxidation, and lipid signaling, thereby supporting FLS expansion, migration, and invasion.31 In parallel, abnormal de novo lipogenesis further reinforces the pathological phenotype of FLS. FASN overexpression can promote fatty acid accumulation, mitochondrial fragmentation, reactive oxygen species (ROS) production, and activation of phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR)/NF-κB signaling, thereby enhancing the invasive and tissue-destructive phenotype of RA-FLS.44 SREBP1-related pathways may also link lipid synthesis with mitochondrial damage, oxidative stress, and inflammatory signaling. For example, iron overload has been reported to activate SREBP1 through the iron regulatory protein 1 (IRP1)–SREBP cleavage-activating protein (SCAP) axis, connecting lipid synthesis, mitochondrial injury, and FLS activation.91 These findings suggest that lipogenesis is not merely a biosynthetic process, but a signaling platform that supports synovial aggression. FAO may also contribute to RA-FLS pathogenic functions, but its role appears to be context-dependent. Under inflammatory cytokine-, adipokine-, or lipid-enriched conditions, enhanced FAO can support FLS activation and invasion. For example, leptin can increase FAO in RA-FLS through the liver kinase B1 (LKB1)–AMP-activated protein kinase (AMPK) pathway, and mitochondrial dynamics-related proteins 49 and 51 kDa (MiD49/51) may promote CPT1A-mediated FAO and FLS invasiveness.48,75 However, impaired FAO and reduced metabolic flexibility have also been observed in at-risk RA stages or in certain RA-FLS populations, indicating that FLS fatty acid metabolism should not be interpreted as simple upregulation of a single pathway.21,92 Fatty acid metabolism also contributes to the inflammatory and matrix-degrading functions of RA-FLS. Free fatty acids can directly promote the release of IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), pro-MMP-1, and MMP-3 from RA synovial fibroblasts.93 Excessive fatty acid influx or lipogenesis may induce lipid accumulation, mitochondrial stress, and ROS generation, thereby activating NF-κB, mitogen-activated protein kinase (MAPK), and PI3K/mTOR pathways and promoting the expression of IL-6, IL-8, MMPs, and RANKL.44 Through these effector molecules, FLS fatty acid metabolic reprogramming can contribute not only to intrinsic FLS activation, but also to immune-cell recruitment, cartilage destruction, and osteoclastogenesis. RA-FLS are also sources of fatty acid-derived lipid mediators. The AA–prostaglandin E2 (PGE2) axis is particularly relevant to FLS-mediated inflammatory feedback. Epidermal growth factor (EGF), adiponectin, and IL-1β can induce cyclooxygenase-2 (COX-2)/microsomal prostaglandin E synthase-1 (mPGES-1) expression and PGE2 production in RA-FLS, whereas PGE2 may regulate FLS responses through prostaglandin E receptor (EP receptor)/cyclic adenosine monophosphate (cAMP) signaling in a context-dependent manner.94–96 Thus, FLS do not merely respond to immune-derived cytokines; they can also shape macrophage, T-cell, and osteoclast precursor functions through lipid mediator production. Overall, fatty acid uptake, lipogenesis, FAO, and lipid mediator generation position RA-FLS as an important metabolic node linking synovial aggression, immune amplification, and bone destruction. The broader role of lipid mediator networks in inflammatory amplification and resolution is discussed in the following section. Taken together, these observations support a mechanistic sequence in which altered lipid supply and lipogenesis reshape membrane and organelle homeostasis, increase redox and mitochondrial stress, activate inflammatory signaling, and reinforce invasive RA-FLS outputs. Nevertheless, much of the mechanistic evidence derives from cell culture and experimental arthritis, and several pathways are supported by a limited number of studies. Independent replication in primary human RA-FLS, spatially resolved synovial samples, and longitudinal cohorts remains necessary. Osteoclasts: Metabolic Effectors of Bone Destruction Progressive bone erosion is a major cause of irreversible structural damage in RA. Osteoclasts, derived from the monocyte/macrophage lineage, are the principal effector cells mediating bone resorption. Although RANKL, TNF-α, IL-1β, and IL-17 promote osteoclastogenesis, osteoclast precursor differentiation, fusion, podosome formation, acidification, and resorptive activity also require metabolic support.97–99 Fatty acid metabolic reprogramming provides an important perspective for understanding how osteoclast-lineage cells acquire efficient fusion and bone-resorbing capacity in an inflammatory microenvironment.17 CPT1A-mediated FAO is closely associated with osteoclast precursor fusion and bone erosion in RA. Osteoclast precursors derived from CD14⁺ monocytes of patients with RA show reduced lipid droplet content and upregulation of FAO-related genes, suggesting a shift from lipid storage toward oxidative utilization. CPT1A, the rate-limiting enzyme for mitochondrial long-chain fatty acid entry and β-oxidation, is increased in RA osteoclast precursors and positively correlates with bone erosion-related indicators. Functionally, CPT1A overexpression enhances osteoclast precursor fusion and bone resorption, whereas CPT1A inhibition or FAO blockade weakens these processes.17 Mechanistically, CPT1A-mediated FAO does more than provide adenosine triphosphate (ATP). It can promote CCAAT/enhancer-binding protein β (C/EBPβ) binding to the promoters of clathrin-related genes such as clathrin light chain A (CLTA) and clathrin heavy chain (CLTC), enhance clathrin-dependent endocytosis, regulate the membrane distribution of fusion-related molecules including dendritic cell-specific transmembrane protein (DC-STAMP), osteoclast stimulatory transmembrane protein (OC-STAMP), CD47, and CD36, and promote podosome formation. This links lipid oxidation, membrane trafficking, and osteoclast fusion to RA bone erosion. CPT1A-mediated FAO should therefore be viewed as one important metabolic program supporting osteoclast fusion and resorptive activity, rather than as the sole determinant of RA bone erosion.100 Different fatty acid species may exert divergent effects on osteoclast differentiation and function. ω-3 PUFAs generally show bone-protective potential. DHA can inhibit macrophage colony-stimulating factor (M-CSF)-induced osteoclast precursor proliferation; suppress RANKL downstream signaling pathways, including c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), p38 MAPK, and NF-κB; downregulate c-Fos and nuclear factor of activated T cells c1 (NFATc1); and promote mature osteoclast apoptosis.76 FFAR4/GPR120 signaling appears to contribute to the inhibitory effect of DHA on inflammation-induced osteoclast formation, whereas EPA and palmitoleic acid may also suppress osteoclastogenesis through lipid receptor- or NF-κB/MAPK-related mechanisms.77,101–103 By contrast, saturated fatty acids such as lauric acid and palmitic acid can enhance osteoclast survival or osteoclastogenesis through lipotoxicity, macrophage inflammatory protein-1α (MIP-1α) production, NF-κB activation, and RANKL-dependent mechanisms. Diacylglycerol O-acyltransferase 1 (DGAT1)-mediated triglyceride synthesis may buffer palmitic acid-induced lipotoxicity by converting excess fatty acids into relatively inert lipid storage forms.104,105 Thus, osteoclast fatty acid metabolism is not uniformly pro-destructive, but depends on fatty acid species, metabolic fate, receptor signaling, lipid storage capacity, and inflammatory context.36,106 In RA, CPT1A-mediated FAO may promote osteoclast fusion and bone resorption, whereas ω-3 PUFAs, especially DHA, and FFAR4/GPR120 signaling may suppress osteoclastogenesis or attenuate the pro-osteoclastogenic inflammatory environment.77,78 Therefore, osteoclast fatty acid metabolic reprogramming represents an important metabolic node linking synovial inflammation to structural joint damage in RA. Fatty Acid-Derived Lipid Mediators: Balancing Inflammatory Amplification and Resolution Fatty acid-derived lipid mediators represent one of the most direct mechanisms by which fatty acid metabolism shapes RA inflammation. Beyond their roles in energy metabolism, membrane remodeling, and FAO-related processes, fatty acids serve as substrates for bioactive lipid mediators that regulate inflammatory amplification, pain sensitization, leukocyte recruitment, efferocytosis, and tissue repair. AA, an ω-6 PUFA, is converted via COX, LOX, and cytochrome P450 pathways into pro-inflammatory mediators such as PGE2, leukotrienes, and HETEs, which promote leukocyte recruitment, pain sensitization, and tissue injury.25 In contrast, ω-3 EPA and DHA are precursors for SPMs, including resolvins, protectins, and maresins, which actively terminate inflammation, enhance efferocytosis, and support tissue repair.49,107 This substrate-dependent balance provides a mechanistic link between fatty acid metabolism, persistent synovitis, and defective resolution in RA. AA-derived mediators are important contributors to synovial inflammatory amplification. Lipidomic analyses of RA synovial fluid indicate remodeling of the local lipid mediator network.35,79 PGE2, generated through the COX-2/mPGES-1 pathway in synovial fibroblasts and macrophages, acts through EP receptors and can cooperate with IL-23–STAT3/RORγt signaling to promote pathogenic Th17 responses.108–110 AA metabolism may also connect inflammation with bone destruction. PGE2 and 5-LOX-derived products can stimulate osteoclast differentiation and bone resorption, suggesting that lipid mediator networks may contribute to inflammatory bone erosion.111–113 Conversely, EPA/DHA-derived SPMs actively promote inflammation resolution rather than merely suppressing inflammation. Detection of SPMs in chronic inflammatory joint effusions indicates that endogenous resolution programs are initiated within inflamed joints.79 Resolvin D1 has been shown to reduce arthritis severity, limit leukocyte infiltration into joints, and protect cartilage in experimental models, supporting the concept that enhancing pro-resolving pathways may help prevent persistent inflammation from progressing toward irreversible tissue destruction.34 Importantly, RA should not be defined by a simple absence of pro-resolving mediators. Severe RA synovial fluid can contain elevated levels of both pro-inflammatory mediators, such as PGE2 and leukotrienes, and pro-resolving mediators, including lipoxins, resolvins, and protectin D1. This pattern suggests that resolution programs may be initiated but remain insufficient to terminate inflammation. Persistent RA inflammation is therefore better interpreted as dominant inflammatory amplification with inadequate pro-resolving signaling, efferocytosis, and tissue repair.79 The balance between pro-inflammatory and pro-resolving mediators is strongly influenced by fatty acid substrate competition. AA is the main precursor for prostaglandins and leukotrienes, whereas EPA and DHA can be incorporated into membrane phospholipids, reduce the relative availability of AA, and shift lipid mediator generation toward ω-3-derived and pro-resolving profiles.114,115 In RA, EPA/DHA or ω-3 PUFA supplementation may improve disease activity and shift lipid mediator profiles toward anti-inflammatory or pro-resolving patterns. Clinical evidence for ω-3 PUFA supplementation in RA remains heterogeneous. In early RA treated with a treat-to-target strategy based on disease-modifying antirheumatic drugs (DMARDs), high-dose fish oil reduced failure of triple DMARD therapy and increased remission, although the 28-joint Disease Activity Score (DAS28) and functional outcomes were not significantly improved.116 Other randomized trials reported no clear overall clinical benefit or similar improvements across different oil-based interventions.117–119 A recent meta-analysis found improvements in fatty acid profiles, triglyceride levels, and tender joint count, but no significant effects on erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), or DAS28.120 These inconsistent findings may reflect differences in dose, treatment duration, baseline diet, concomitant DMARD therapy, disease activity, and patient characteristics. Therefore, ω-3 PUFAs should be regarded as adjunctive modulators rather than substitutes for DMARDs.121–124 The variability of supplementation trials does not negate the biological importance of lipid mediator balance, but indicates that dietary ω-3 intake does not uniformly translate into predictable changes in joint mediator networks or clinical outcomes. At the mechanistic level, fatty acid-derived lipid mediators regulate a dynamic equilibrium between inflammatory amplification and resolution. AA-derived PGE2, leukotrienes, and HETEs can amplify synovial inflammation and bone remodeling, whereas EPA/DHA-derived SPMs promote efferocytosis, resolution, and tissue repair. Pharmacologically or nutritionally restoring this lipid mediator balance may provide an adjunctive strategy for limiting persistent synovitis and structural joint damage in RA. Therapeutic Implications of Targeting Fatty Acid Metabolic Reprogramming in RA The mechanisms discussed above suggest that fatty acid metabolic reprogramming may provide several therapeutic entry points for limiting persistent inflammation and structural damage in RA. These include restricting pathogenic fatty acid uptake and de novo lipogenesis, modulating FAO in a cell-selective manner, restoring lipid mediator balance, and regulating systemic lipid–immune interactions. Because fatty acid metabolism is essential for normal energy production, membrane homeostasis, tissue repair, and immune function, therapeutic development should avoid broad systemic inhibition and instead emphasize cell selectivity, synovial targeting, disease-stage stratification, reversibility, pharmacodynamic biomarkers, and systematic safety evaluation. From a translational perspective, ω-3 nutritional approaches have the greatest human exposure but variable efficacy; receptor-directed, SPM-based, and microbiota-related approaches remain preclinical or early translational; and direct inhibition of broadly expressed transport, lipogenesis, or oxidation pathways is likely to require targeted delivery. Direct metabolic strategies are summarized in Table 3, and indirect or regulatory approaches are summarized in Table 4.30,92 Table 3Direct Targeting of Fatty Acid Metabolic Pathways in Rheumatoid ArthritisTherapeutic DirectionCandidate Targets/PathwaysIntended Pathological ProcessRationaleDevelopmental StageLimitations/Future DirectionsRestricting pathogenic fatty acid uptake/transportCD36, FABPs, FATPs/SLC27A family membersRA-FLS activation, CD8+ T-cell inflammatory activation, and lipid-driven synovial aggression.Limiting excessive lipid substrate supply may reduce membrane remodeling, lipid raft signaling, mitochondrial oxidation, and inflammatory activation.31,72PreclinicalFatty acid transport is required by normal tissues and immune cells; synovium-targeted or cell-selective delivery and cell-type validation are needed.Suppressing excessive de novo lipogenesisFASN, ACC1, SCD1, SREBP1, and SCAP-related pathwaysRA-FLS proliferation, lipid accumulation, mitochondrial stress, ROS/NF-κB signaling, inflammatory activation, and Th17 differentiation.De novo lipogenesis supports membrane expansion, inflammatory signaling, and aggressive RA-FLS behavior; inhibition of FASN/SREBP1-related pathways may reduce synovial aggression.44,71PreclinicalBroad inhibition may affect normal immune function and metabolic homeostasis; cell-specific validation, dose optimization, and safety assessment are required.Cell-selective modulation of FAOCPT1A-dependent FAO in osteoclast precursors and activated RA-FLS; CPT2-related mitochondrial FAO in Treg cellsOsteoclast precursor fusion and bone resorption, RA-FLS invasiveness, and impaired Treg suppressive function.Pathological FAO may promote osteoclast activity and RA-FLS invasion, whereas protective FAO supports Treg suppressive function.17,33,48,125Preclinical/mechanisticFAO should not be inhibited indiscriminately; ideal strategies should suppress pathogenic FAO while preserving or restoring Treg FAO.Note: The developmental stage is a qualitative assessment based on the evidence summarized in this review and does not indicate regulatory approval.Abbreviations: ACC1, acetyl-CoA carboxylase 1; CD36, cluster of differentiation 36; CD8, cluster of differentiation 8; CPT1A, carnitine palmitoyltransferase 1A; CPT2, carnitine palmitoyltransferase 2; FABPs, fatty acid-binding proteins; FAO, fatty acid β-oxidation; FASN, fatty acid synthase; FATPs/SLC27A, fatty acid transport proteins/solute carrier family 27A; NF-κB, nuclear factor-κB; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; ROS, reactive oxygen species; SCAP, SREBP cleavage-activating protein; SCD1, stearoyl-CoA desaturase 1; SREBP1, sterol regulatory element-binding protein 1; Th17, T helper 17; Treg, regulatory T cell. Table 4Indirect and Regulatory Approaches Targeting Fatty Acid Metabolism in Rheumatoid ArthritisTherapeutic DirectionCandidate Targets/PathwaysIntended Pathological ProcessRationaleDevelopmental StageLimitations/Future DirectionsRestoring lipid mediator balanceAA-COX/LOX pathways; EPA/DHA-derived SPMs, including resolvins, protectins, and maresinsPersistent synovitis, pain sensitization, leukocyte recruitment, defective resolution, cartilage injury, and inflammatory bone remodeling.Reducing AA-derived pro-inflammatory mediators while enhancing EPA/DHA-derived pro-resolving mediators may promote inflammation resolution and tissue repair.25,34,35,79Clinical adjunct (ω-3 PUFAs); preclinical/early translational (SPMs)ω-3 PUFA supplementation and SPM-based approaches should be viewed as adjunctive strategies; effects may depend on dose, duration, baseline diet, disease activity, and patient selection.Modulating fatty acid receptor signalingFFAR4/GPR120, GPR84, EP receptors, and LPA receptors; SPM receptorsTh1/Th17/Treg imbalance, CD8+ T-cell activation, osteoclastogenesis, RA-FLS activation, and inflammatory feedback.FFAR4/GPR120 activation may alleviate arthritis and osteoclastogenesis; GPR84 blockade may reduce CD8+ T-cell inflammatory function; LPA and EP receptor pathways regulate RA-FLS and inflammatory responses.58,72,77,126PreclinicalReceptor effects are cell type-specific and ligand-dependent; spatial and single-cell validation in RA synovium is needed.Modulating gut microbiota-derived fatty acid metabolitesSCFAs, including butyrate, propionate, and acetate; AhR, GPCRs (including FFA2), HDAC, and AMPK/mTOR-related signalingTreg/Th17 imbalance, Breg function, intestinal barrier integrity, osteoclast differentiation, and systemic immune tone.SCFAs link diet, gut microbiota, immune tolerance, and bone metabolism; butyrate/SCFAs may enhance regulatory B-cell or T-cell responses and suppress arthritis.74,127–130Preclinical/early translationalOptimal dose, treatment duration, patient selection, and combination value with DMARDs remain unclear.Natural products and traditional medicine-derived interventionsAMPK signaling, fatty acid transport, lipid peroxidation, gut-joint axis, RA-FLS lipid metabolism, and macrophage-adipose tissue crosstalkMulti-level regulation of immune inflammation, synovial aggression, oxidative stress, gut-joint interaction, and bone destruction.Multi-component interventions may match the multicellular nature of RA fatty acid metabolic remodeling and immune–synovial–bone interactions; examples affect carnitine/butyrate metabolism, exosomal lipid pathways, or fatty acid metabolism.84,131–134Predominantly preclinicalMechanistic interpretation is difficult; future studies should include target validation, cell-specific experiments, metabolic flux tracing, and metabolite supplementation or blockade.Note: The developmental stage is a qualitative assessment based on the evidence summarized in this review and does not indicate regulatory approval.Abbreviations: AA, arachidonic acid; AhR, aryl hydrocarbon receptor; AMPK, AMP-activated protein kinase; Breg, regulatory B cell; CD8, cluster of differentiation 8; COX, cyclooxygenase; DHA, docosahexaenoic acid; DMARDs, disease-modifying antirheumatic drugs; EPA, eicosapentaenoic acid; EP receptors, prostaglandin E receptors; FFA2, free fatty acid receptor 2; FFAR4/GPR120, free fatty acid receptor 4/G protein-coupled receptor 120; GPCRs, G protein-coupled receptors; GPR84, G protein-coupled receptor 84; HDAC, histone deacetylase; LOX, lipoxygenase; LPA, lysophosphatidic acid; mTOR, mechanistic target of rapamycin; PUFA, polyunsaturated fatty acid; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; SCFAs, short-chain fatty acids; SPMs, specialized pro-resolving mediators; Th1, T helper 1; Th17, T helper 17; Treg, regulatory T cell. Table 3Direct Targeting of Fatty Acid Metabolic Pathways in Rheumatoid ArthritisTherapeutic DirectionCandidate Targets/PathwaysIntended Pathological ProcessRationaleDevelopmental StageLimitations/Future DirectionsRestricting pathogenic fatty acid uptake/transportCD36, FABPs, FATPs/SLC27A family membersRA-FLS activation, CD8+ T-cell inflammatory activation, and lipid-driven synovial aggression.Limiting excessive lipid substrate supply may reduce membrane remodeling, lipid raft signaling, mitochondrial oxidation, and inflammatory activation.31,72PreclinicalFatty acid transport is required by normal tissues and immune cells; synovium-targeted or cell-selective delivery and cell-type validation are needed.Suppressing excessive de novo lipogenesisFASN, ACC1, SCD1, SREBP1, and SCAP-related pathwaysRA-FLS proliferation, lipid accumulation, mitochondrial stress, ROS/NF-κB signaling, inflammatory activation, and Th17 differentiation.De novo lipogenesis supports membrane expansion, inflammatory signaling, and aggressive RA-FLS behavior; inhibition of FASN/SREBP1-related pathways may reduce synovial aggression.44,71PreclinicalBroad inhibition may affect normal immune function and metabolic homeostasis; cell-specific validation, dose optimization, and safety assessment are required.Cell-selective modulation of FAOCPT1A-dependent FAO in osteoclast precursors and activated RA-FLS; CPT2-related mitochondrial FAO in Treg cellsOsteoclast precursor fusion and bone resorption, RA-FLS invasiveness, and impaired Treg suppressive function.Pathological FAO may promote osteoclast activity and RA-FLS invasion, whereas protective FAO supports Treg suppressive function.17,33,48,125Preclinical/mechanisticFAO should not be inhibited indiscriminately; ideal strategies should suppress pathogenic FAO while preserving or restoring Treg FAO.Note: The developmental stage is a qualitative assessment based on the evidence summarized in this review and does not indicate regulatory approval.Abbreviations: ACC1, acetyl-CoA carboxylase 1; CD36, cluster of differentiation 36; CD8, cluster of differentiation 8; CPT1A, carnitine palmitoyltransferase 1A; CPT2, carnitine palmitoyltransferase 2; FABPs, fatty acid-binding proteins; FAO, fatty acid β-oxidation; FASN, fatty acid synthase; FATPs/SLC27A, fatty acid transport proteins/solute carrier family 27A; NF-κB, nuclear factor-κB; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; ROS, reactive oxygen species; SCAP, SREBP cleavage-activating protein; SCD1, stearoyl-CoA desaturase 1; SREBP1, sterol regulatory element-binding protein 1; Th17, T helper 17; Treg, regulatory T cell. Direct Targeting of Fatty Acid Metabolic Pathways in Rheumatoid Arthritis Note: The developmental stage is a qualitative assessment based on the evidence summarized in this review and does not indicate regulatory approval. Abbreviations: ACC1, acetyl-CoA carboxylase 1; CD36, cluster of differentiation 36; CD8, cluster of differentiation 8; CPT1A, carnitine palmitoyltransferase 1A; CPT2, carnitine palmitoyltransferase 2; FABPs, fatty acid-binding proteins; FAO, fatty acid β-oxidation; FASN, fatty acid synthase; FATPs/SLC27A, fatty acid transport proteins/solute carrier family 27A; NF-κB, nuclear factor-κB; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; ROS, reactive oxygen species; SCAP, SREBP cleavage-activating protein; SCD1, stearoyl-CoA desaturase 1; SREBP1, sterol regulatory element-binding protein 1; Th17, T helper 17; Treg, regulatory T cell. Table 4Indirect and Regulatory Approaches Targeting Fatty Acid Metabolism in Rheumatoid ArthritisTherapeutic DirectionCandidate Targets/PathwaysIntended Pathological ProcessRationaleDevelopmental StageLimitations/Future DirectionsRestoring lipid mediator balanceAA-COX/LOX pathways; EPA/DHA-derived SPMs, including resolvins, protectins, and maresinsPersistent synovitis, pain sensitization, leukocyte recruitment, defective resolution, cartilage injury, and inflammatory bone remodeling.Reducing AA-derived pro-inflammatory mediators while enhancing EPA/DHA-derived pro-resolving mediators may promote inflammation resolution and tissue repair.25,34,35,79Clinical adjunct (ω-3 PUFAs); preclinical/early translational (SPMs)ω-3 PUFA supplementation and SPM-based approaches should be viewed as adjunctive strategies; effects may depend on dose, duration, baseline diet, disease activity, and patient selection.Modulating fatty acid receptor signalingFFAR4/GPR120, GPR84, EP receptors, and LPA receptors; SPM receptorsTh1/Th17/Treg imbalance, CD8+ T-cell activation, osteoclastogenesis, RA-FLS activation, and inflammatory feedback.FFAR4/GPR120 activation may alleviate arthritis and osteoclastogenesis; GPR84 blockade may reduce CD8+ T-cell inflammatory function; LPA and EP receptor pathways regulate RA-FLS and inflammatory responses.58,72,77,126PreclinicalReceptor effects are cell type-specific and ligand-dependent; spatial and single-cell validation in RA synovium is needed.Modulating gut microbiota-derived fatty acid metabolitesSCFAs, including butyrate, propionate, and acetate; AhR, GPCRs (including FFA2), HDAC, and AMPK/mTOR-related signalingTreg/Th17 imbalance, Breg function, intestinal barrier integrity, osteoclast differentiation, and systemic immune tone.SCFAs link diet, gut microbiota, immune tolerance, and bone metabolism; butyrate/SCFAs may enhance regulatory B-cell or T-cell responses and suppress arthritis.74,127–130Preclinical/early translationalOptimal dose, treatment duration, patient selection, and combination value with DMARDs remain unclear.Natural products and traditional medicine-derived interventionsAMPK signaling, fatty acid transport, lipid peroxidation, gut-joint axis, RA-FLS lipid metabolism, and macrophage-adipose tissue crosstalkMulti-level regulation of immune inflammation, synovial aggression, oxidative stress, gut-joint interaction, and bone destruction.Multi-component interventions may match the multicellular nature of RA fatty acid metabolic remodeling and immune–synovial–bone interactions; examples affect carnitine/butyrate metabolism, exosomal lipid pathways, or fatty acid metabolism.84,131–134Predominantly preclinicalMechanistic interpretation is difficult; future studies should include target validation, cell-specific experiments, metabolic flux tracing, and metabolite supplementation or blockade.Note: The developmental stage is a qualitative assessment based on the evidence summarized in this review and does not indicate regulatory approval.Abbreviations: AA, arachidonic acid; AhR, aryl hydrocarbon receptor; AMPK, AMP-activated protein kinase; Breg, regulatory B cell; CD8, cluster of differentiation 8; COX, cyclooxygenase; DHA, docosahexaenoic acid; DMARDs, disease-modifying antirheumatic drugs; EPA, eicosapentaenoic acid; EP receptors, prostaglandin E receptors; FFA2, free fatty acid receptor 2; FFAR4/GPR120, free fatty acid receptor 4/G protein-coupled receptor 120; GPCRs, G protein-coupled receptors; GPR84, G protein-coupled receptor 84; HDAC, histone deacetylase; LOX, lipoxygenase; LPA, lysophosphatidic acid; mTOR, mechanistic target of rapamycin; PUFA, polyunsaturated fatty acid; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; SCFAs, short-chain fatty acids; SPMs, specialized pro-resolving mediators; Th1, T helper 1; Th17, T helper 17; Treg, regulatory T cell. Indirect and Regulatory Approaches Targeting Fatty Acid Metabolism in Rheumatoid Arthritis Note: The developmental stage is a qualitative assessment based on the evidence summarized in this review and does not indicate regulatory approval. Abbreviations: AA, arachidonic acid; AhR, aryl hydrocarbon receptor; AMPK, AMP-activated protein kinase; Breg, regulatory B cell; CD8, cluster of differentiation 8; COX, cyclooxygenase; DHA, docosahexaenoic acid; DMARDs, disease-modifying antirheumatic drugs; EPA, eicosapentaenoic acid; EP receptors, prostaglandin E receptors; FFA2, free fatty acid receptor 2; FFAR4/GPR120, free fatty acid receptor 4/G protein-coupled receptor 120; GPCRs, G protein-coupled receptors; GPR84, G protein-coupled receptor 84; HDAC, histone deacetylase; LOX, lipoxygenase; LPA, lysophosphatidic acid; mTOR, mechanistic target of rapamycin; PUFA, polyunsaturated fatty acid; RA, rheumatoid arthritis; RA-FLS, rheumatoid arthritis fibroblast-like synoviocytes; SCFAs, short-chain fatty acids; SPMs, specialized pro-resolving mediators; Th1, T helper 1; Th17, T helper 17; Treg, regulatory T cell. Restricting Pathogenic Fatty Acid Uptake and de Novo Synthesis Limiting pathogenic fatty acid utilization can be achieved by targeting fatty acid uptake, intracellular trafficking, or de novo synthesis. CD36, FABPs, and FATPs/SLC27A regulate fatty acid uptake and intracellular distribution, thereby influencing whether fatty acids are used for membrane synthesis, lipid storage, mitochondrial oxidation, or lipid signaling.31 In RA, CD36-mediated fatty acid metabolic reprogramming has been reported to promote FLS activation and joint destruction, whereas CD36 inhibition alleviates synovial inflammation and bone erosion in experimental models. Fatty acid transport and sensing pathways may also sustain pathogenic immune responses, as suggested by studies showing that FABP4 and GPR84 support RA CD8⁺ T-cell activation.72 De novo lipogenesis, involving FASN, ACC, SCD1, SREBP1, and SCAP, provides lipid substrates for FLS proliferation, membrane remodeling, inflammatory signaling, and potentially Th17 differentiation.66,71 Targeting FASN or related lipogenic pathways may suppress the aggressive FLS phenotype, reduce lipid accumulation, alleviate mitochondrial stress, and decrease inflammatory activation in experimental settings.44 Nevertheless, fatty acid uptake and synthesis are also required by normal immune cells and metabolically active tissues. Therefore, synovium-targeted or cell-specific delivery strategies will be needed to improve therapeutic selectivity and limit systemic metabolic toxicity. Cell-Selective Modulation of FAO Therapeutic modulation of FAO is more complex because its effects are highly cell type-dependent. In osteoclast precursors, CPT1A-mediated FAO promotes cell fusion and bone resorption through a C/EBPβ–clathrin-related membrane trafficking program; inhibition of CPT1A or FAO reduces osteoclast activity.17 In RA-FLS, inflammation- or adipokine-induced FAO may also support pro-inflammatory and invasive phenotypes.48 These findings suggest that pathological FAO in osteoclast precursors and activated FLS may represent a therapeutic target. However, FAO should not be viewed as uniformly pathogenic. Treg cells require mitochondrial FAO to maintain suppressive function, and impaired CPT2-related FAO with reduced CTLA4 surface stability is associated with Treg dysfunction in RA.33 Therefore, FAO-targeted therapy should shift from broad systemic inhibition toward cell-selective modulation. An ideal strategy would suppress pathological FAO in osteoclast precursors and activated FLS while preserving or restoring protective FAO in Treg cells.125 This distinction is essential to avoid therapeutic approaches that reduce tissue-destructive metabolism but simultaneously impair immune tolerance. Restoring Lipid Mediator Balance and Inflammation Resolution Restoring the balance between pro-inflammatory and pro-resolving lipid mediators represents another therapeutic direction. EPA and DHA can compete with AA, reduce ω-6-derived pro-inflammatory mediator generation, and serve as substrates for SPMs.121,124 SPMs actively promote inflammation termination, macrophage-mediated efferocytosis, and tissue repair. Resolvin D1 and related mediators have shown protective effects in experimental arthritis models, indicating that pro-resolving pathways may help restrain persistent synovitis and cartilage damage.25,34 Fatty acid receptor signaling may further contribute to this rebalancing strategy. FFAR4/GPR120, a receptor for long-chain ω-3 fatty acids, can mediate anti-inflammatory effects by inhibiting NF-κB and inflammasome activation.58,135 Other lipid mediator-related pathways, including COX/LOX metabolism, lysophosphatidic acid receptor signaling, and SPM receptor activation, may also influence synovial inflammation, FLS survival, osteoclast activation, and resolution responses.126 These approaches should be considered adjunctive interventions that restore a dynamic inflammatory–resolution balance, rather than replacements for DMARDs. Systemic Regulation of Lipid–Immune Interactions Systemic interventions may indirectly modulate RA inflammation through lipid metabolism, gut microbiota-derived metabolites, oxidative stress, intestinal barrier function, and immune tolerance. Short-chain fatty acids (SCFAs), including butyrate, propionate, and acetate, link diet, microbiota, and immune homeostasis.127,136 They can influence the Treg/Th17 balance, regulatory B-cell function, intestinal barrier integrity, and osteoclast differentiation through histone deacetylase inhibition, G protein-coupled receptors, and AMPK/mTOR signaling.74,128,131 Higher SCFA levels have been associated with reduced progression to clinical arthritis in at-risk individuals, and butyrate has been reported to suppress arthritis by enhancing AhR-dependent regulatory B-cell function.74,129,130 However, optimal dosing, treatment duration, patient selection, and combination value with DMARDs remain uncertain. Natural products and multi-component interventions, including traditional Chinese medicine formulas, may provide additional examples of systemic lipid–immune modulation. These interventions may influence SCFA metabolism, AMPK signaling, lipid peroxidation or ferroptosis, fatty acid transport, gut–joint axis interactions, FLS lipid metabolism, or macrophage–adipose tissue crosstalk.84,131–134 Their multi-component and multi-target characteristics may match the complexity of the RA immune–synovial–bone destruction framework, but they also complicate mechanistic interpretation. Future studies should move beyond descriptive animal models, metabolomics, microbiota sequencing, and network pharmacology by incorporating cell-specific experiments, stable isotope metabolic flux tracing, metabolite supplementation or blockade, and target validation. Challenges and Future Directions Although fatty acid metabolic reprogramming is increasingly implicated in RA synovitis, immune imbalance, and bone destruction, the field still needs to move from omics-based associations toward mechanistic validation and translational assessment.30,39 Key unresolved questions concern the responsible cell types, disease stages, causal roles, therapeutic selectivity, and safety of targeting fatty acid metabolic pathways. Future studies should distinguish systemic dyslipidemia, local synovial lipid remodeling, and cell-intrinsic fatty acid metabolic reprogramming, because these processes may have different mechanisms and therapeutic implications. First, cell specificity and spatial heterogeneity remain insufficiently defined.137 RA synovium comprises FLS, macrophages, T cells, B cells, endothelial cells, and osteoclast precursors, each with distinct dependencies on fatty acid uptake, synthesis, FAO, lipid storage, and mediator generation. Yet most studies still focus on single cell types or isolated metabolic nodes.90,138 Integrating single-cell transcriptomics, spatial lipidomics, imaging mass spectrometry, and stable isotope metabolic flux tracing will be essential to map fatty acid metabolic programs across the synovial lining, inflammatory infiltrates, lymphoid aggregates, and bone erosion sites.9,139 Second, the causal position of fatty acid metabolic shifts during RA development remains unclear. Altered SCFA levels in at-risk individuals and impaired FLS metabolic flexibility before overt synovitis suggest early involvement.21,129 However, inflammation, hypoxia, oxidative stress, and tissue injury can also secondarily reshape fatty acid metabolism. Longitudinal at-risk and early RA cohorts, paired pre- and post-treatment samples, and cell-specific intervention models are needed to determine whether fatty acid metabolic changes act as initiating drivers, amplifiers of chronic inflammation, or compensatory consequences. Third, FAO requires precise interpretation. CPT1A-mediated FAO promotes osteoclast fusion and bone resorption, and adipokine-induced FAO may support invasive FLS phenotypes.17,48 In contrast, Treg cells require FAO for suppressive function, and impaired FAO correlates with reduced CTLA4 stability and Treg dysfunction.33 Future studies should specify the involved cell type, substrate source, mitochondrial state, disease stage, and functional output instead of classifying FAO as globally pathogenic or protective. Fourth, lipid mediator dysregulation reflects a disturbed dynamic balance rather than simple binary changes. RA synovial fluid may contain elevated levels of both pro-inflammatory mediators and pro-resolving mediators.35,79 Future studies should assess mediator ratios, receptor expression, downstream signaling, and functional outputs, including macrophage efferocytosis, tissue clearance, pain, cartilage protection, and bone remodeling. Fifth, translational development requires safety-oriented targeting. Fatty acid uptake, synthesis, and oxidation are essential for the heart, liver, skeletal muscle, adipose tissue, and normal immune cells.140 Broad, non-selective systemic inhibition of fatty acid metabolic pathways may therefore cause systemic metabolic toxicity or impair protective immune functions. More feasible strategies may include synovium-targeted delivery, cell-selective nanoparticles, prodrug approaches, local intra-articular delivery, and disease-stage-stratified interventions.141,142 Candidate targets include CD36/FASN/SREBP1-related pathways in RA-FLS, CPT1A-dependent FAO in osteoclast precursors, FAO restoration in Treg cells, and lipid mediator receptor signaling pathways. Sixth, several cross-cutting dimensions remain incompletely integrated into the immune–synovial–bone destruction framework. Lipid peroxidation and ferroptosis may connect fatty acid composition and oxidative stress with RA-FLS dysfunction, inflammatory amplification, and structural tissue injury, but their cell-specific and causal roles in RA remain incompletely defined.37 Sex-dependent differences in fatty acid uptake, storage, and oxidation may modify metabolic programs across immune cells, synovial fibroblasts, and osteoclast-lineage cells and may contribute to heterogeneity in disease severity and treatment response.143 B-cell fatty acid metabolism may influence the immune-dysregulation component of the framework, but it remains unclear whether altered fatty acid uptake, lipid-droplet formation, mitochondrial FAO, and lipid-mediator responsiveness directly regulate autoantibody production or regulatory B-cell function, or mainly reflect systemic immune activation.88,144 Future studies should therefore incorporate sex-stratified cohorts, cell-specific metabolic-flux analysis, and functional validation in primary human cells to establish causality and define how these dimensions fit within the proposed framework. Conclusion Fatty acid metabolic reprogramming provides a framework that integrates four interdependent components of RA pathogenesis: inflammatory amplification, defective resolution, RA-FLS-driven synovial aggression, and osteoclast-mediated bone destruction. This perspective complements the traditional immunological paradigm by showing how lipid substrate handling, oxidative metabolism, storage, and mediator generation shape pathogenic cellular functions and influence disease progression. In this sense, RA is not only immune-mediated but also metabolically conditioned within the joint microenvironment. Current evidence suggests that fatty acid metabolism is not merely a secondary consequence of inflammation, but may actively participate in RA pathogenesis through cell type-specific and context-dependent mechanisms. In monocytes/macrophages and T cells, fatty acid-related metabolic changes can regulate chemokine release, inflammatory activation, effector responses, Treg-mediated immune tolerance, and inflammatory cell death. In RA-FLS, altered fatty acid uptake, de novo lipogenesis, FAO, and lipid mediator production may support aggressive, pro-inflammatory, and matrix-degrading phenotypes. In osteoclast-lineage cells, CPT1A-mediated FAO may promote precursor fusion and bone resorption, thereby linking inflammatory signals to structural bone destruction. In parallel, an imbalance between AA-derived inflammatory mediators and EPA/DHA-derived SPMs may sustain synovitis and impair inflammation resolution. These conclusions remain constrained by the limited availability of longitudinal human studies, incomplete direct measurements of metabolic flux, reliance on experimental arthritis models and isolated cell systems, and uncertainty regarding causal direction and cell-selective therapeutic windows. Therefore, the key issue is not whether fatty acid metabolism is globally enhanced or suppressed, but how specific fatty acid metabolic programs are rewired within distinct pathological cells, lipid substrate environments, and disease stages. From a therapeutic perspective, targeting fatty acid metabolic reprogramming should be viewed as an adjunctive anti-inflammatory and immunometabolic strategy rather than a replacement for current DMARDs, biologic therapies, or targeted synthetic agents. Potential approaches include restricting pathogenic fatty acid uptake and de novo lipogenesis, selectively modulating FAO in RA-FLS and osteoclast precursors while preserving FAO-dependent immune tolerance in Treg cells, and restoring the balance between pro-inflammatory and pro-resolving lipid mediators. Because fatty acid metabolism is essential for normal tissue homeostasis and protective immune function, future interventions should emphasize cell specificity, synovial targeting, disease-stage stratification, and systematic safety evaluation. Clarifying the cell-specific mechanisms, lipid substrate dependencies, causal roles, and therapeutic boundaries of this metabolic network will be critical for translating fatty acid metabolism-targeted approaches into more precise adjunctive anti-inflammatory interventions for RA. Such advances may ultimately expand treatment options for patients who do not achieve sustained remission with current therapies and may also provide a conceptual framework for investigating metabolic reprogramming in other chronic inflammatory autoimmune diseases.